Abstract
The drug development process has become extremely competitive over the past decade as regulations and patient safety concerns require lengthy and costly investigations to evaluate new products. The cost of development of a pharmaceutical product must be less than the return on investment over the market lifetime. To ensure profitability in this competitive environment, new products must penetrate global markets rapidly. Prior to entry, regulatory review and approval of a market application is required in each country.
This overview chronicles the rapid and successful drug development and global market application filing of Sevoflurane. In March 1992, Abbott Laboratories’ Hospital Products Division began to organize a clinical submission plan for Sevoflurane, a new inhalational anesthetic. To date, Sevoflurane is approved in 46 countries, including the United States. It has been well accepted in all markets. Worldwide, over 11 million patients have been exposed to Sevoflurane.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Regan BM, Zimmerman SR. Anesthetic activity vs. chemical constitution of fluorinated methyl isopropyl ethers. Fed Proc. 1971;30(2):442.
Wallin RF, Napoli MD. Sevoflurane (fluoromethyl 1,1,1,3,3,3-Hexafluoro-2-Propyl Ether): A new inhalational anesthetic agent. Fed Proc. 1971;30(2):442.
Mapleson WW. Effect of age on MA. in humans: A meta-analysis. Br J of Anaesth. 1996;76:179–85.
Sevoflurane Package Insert. June 1995.
Author information
Authors and Affiliations
Consortia
Additional information
The Sevoflurane Venture Team recognizes these individuals: A. Adee, A. Bartley-Arquilla, D. Belongia, S. Bohannon, C. Frosch, S. Galvez, J. Jennings, M. Klemz, Z. Latif, P. Pichotta, G. Pratt, P. Prokocimer, J. Sayre, T. Stickler, P. Vandergrift, and B. Willms; the Hospital Products Division of Abbott Laboratories: C. Begley, D. Cunningham, D. Grabenkort, J. Garapolo, S. Huang, J. Joseph, J. Kringel, J. Leedy, L. Meyer, S. Murphy, K. Pope, G. Ramsay, and M. Szela; the Pharmaceutical Products Division of Abbott Laboratories: B. Bopp, S. Burke, P. Cusick, F. Fort, M. Friedman, W. Giardina, M. Karol, K. Keller, C. Lanni, J. Machinist, D. Moyse, R. Patterson, and B. Sonders; the International Division of Abbott Laboratories: R. Bachand, D. Chapman, N. Conway, C. Fulwell, P. Guzek, M. Hodkinson, R. Horder, W. Mann, L. Mershimer, U. Ortell, J. Y. Paveé, and C. Ward; Maruishi Pharmaceuticals: K. Habuchi, K. Inoue, N. Inoue, and N. Satoh; Central Glass Company Limited: S. Inoue and Y. Kumagai; Ledell, Inc.: K. Hembrey, E. Hodosh, C. Leman, S. Rogers, and J. Wu; and outside contractors: M. Anderson, M. DeLeon, L. Garcia, V. Holem, S. Katz, J. Patrick, and N. Siddique.
Rights and permissions
About this article
Cite this article
Callan, C., Delgado-Herrera, L., Guzek, D. et al. An Historical Perspective of the Successful Development of Sevoflurane. Ther Innov Regul Sci 32, 119–127 (1998). https://doi.org/10.1177/009286159803200116
Published:
Issue Date:
DOI: https://doi.org/10.1177/009286159803200116